Intracerebral hemorrhage associated with oral anticoagulant therapy: Current practices and unresolved questions

Thorsten Steiner, Jonathan Rosand, Michael Diringer

Research output: Contribution to journalReview articlepeer-review

262 Scopus citations

Abstract

Background and Purpose - Life-threatening intracranial hemorrhage, predominantly intracerebral hemorrhage (ICH), is the most serious complication of oral anticoagulant therapy (OAT), with mortality in excess of 50%. Early intervention focuses on rapid correction of coagulopathy in order to prevent continued bleeding. Summary of Review - This article reviews the epidemiology of OAT-associated ICH (OAT-ICH), and current treatment options, with the aim of providing a framework for future studies of unresolved questions. A number of acute treatments are available, but all have a significant risk of inducing thrombosis and other side effects, and vary in their rapidity of effect: vitamin K (very slow response time), fresh frozen plasma (slow response time, large volume of fluid required, transfusion-related acute lung injury), prothrombin complex concentrates, and recombinant activated factor VII. Current practice is to administer a combination of vitamin K and either fresh frozen plasma or prothrombin complex concentrates; the occasional use of recombinant activated factor VII has been reported. No prospective study has addressed the efficacy of, or outcomes from, the use of these practices. Conclusions - Current management of OAT-ICH is varied and not based on evidence from randomized controlled trials. Well-designed clinical trials are essential if we are to identify the effective acute treatments for OAT-ICH that are urgently needed.

Original languageEnglish
Pages (from-to)256-262
Number of pages7
JournalStroke
Volume37
Issue number1
DOIs
StatePublished - Jan 2006

Keywords

  • Etiology
  • Intracerebral hemorrhage
  • Oral anticoagulant agents
  • Therapy
  • Warfarin

Fingerprint

Dive into the research topics of 'Intracerebral hemorrhage associated with oral anticoagulant therapy: Current practices and unresolved questions'. Together they form a unique fingerprint.

Cite this